Marcus Webb
Analyst

Marcus Webb

Senior Markets Analyst

Marcus has over 12 years of experience covering equity markets, earnings reports, and macroeconomic trends. He specializes in large-cap stocks and sector rotations.

Marcus Webb's Articles (318)
Strategy Stock Surges 7% as Analysts Endorse New Capital Allocation Plan
Stocks
Strategy Stock Surges 7% as Analysts Endorse New Capital Allocation Plan
Rivian Stock Surges 12% on Q2 Delivery Beat, 2026 Guidance Raised to 65,000 Units
Stocks
Rivian Stock Surges 12% on Q2 Delivery Beat, 2026 Guidance Raised to 65,000 Units
Nvidia Slips Below $200 as AI Enthusiasm Shifts to Memory and CPU Plays
Stocks
Nvidia Slips Below $200 as AI Enthusiasm Shifts to Memory and CPU Plays
AeroVironment Shares Jump 4% on $500M Army Counter-Drone Contract, Record Revenue
Stocks
AeroVironment Shares Jump 4% on $500M Army Counter-Drone Contract, Record Revenue
Shopify Stock Eyes $150 as Bullish Inverted H&S Pattern Emerges
Stocks
Shopify Stock Eyes $150 as Bullish Inverted H&S Pattern Emerges
Why Prop Firms Must Upgrade Infrastructure to Survive Market Volatility
Markets
Why Prop Firms Must Upgrade Infrastructure to Survive Market Volatility
OpenAI Proposes 5% Government Stake as AI Regulation Intensifies
Stocks
OpenAI Proposes 5% Government Stake as AI Regulation Intensifies
Apple's Five-iPhone Blitz Tests Premium Valuation Amid Rising Memory Costs
Stocks
Apple's Five-iPhone Blitz Tests Premium Valuation Amid Rising Memory Costs
Memory Stocks Plunge: Samsung, SK Hynix, Kioxia Drop Up to 33% on Profit-Taking and Legal Woes
Stocks
Memory Stocks Plunge: Samsung, SK Hynix, Kioxia Drop Up to 33% on Profit-Taking and Legal Woes
Dow Hits Record 52,743 Then Fades as Chip Profit-Taking Drags Nasdaq Lower
Stocks
Dow Hits Record 52,743 Then Fades as Chip Profit-Taking Drags Nasdaq Lower
Microsoft Stock Jumps 4% on Haleon AI Deal, Job Cut Reports
Stocks
Microsoft Stock Jumps 4% on Haleon AI Deal, Job Cut Reports
Hims & Hers Surges 9% on Canaccord Target Hike Ahead of FDA Peptide Review
Stocks
Hims & Hers Surges 9% on Canaccord Target Hike Ahead of FDA Peptide Review